{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:43:43Z","timestamp":1793785423195,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical research for patients with rare cancers has been very challenging. First and foremost, patient accrual to clinical trials typically requires a network, cooperative group, or even international collaboration in order to achieve the necessary numbers of patients to adequately evaluate a new treatment or intervention. Similar limitations in preclinical models and in the understanding the natural history of the disease or pertinent prognostic factors further impede the development of hypothesis-based, appropriately powered clinical trials. However, despite these challenges, several studies in rare cancers, including ependymoma and subependymal giant cell astrocytoma, have helped to establish new treatment regimens. Importantly, in these seminal trials, patient outcomes measures were critical in describing the clinical benefit derived from the therapy, underscoring the need to incorporate these measures in future trials. While obstacles still remain, novel and creative approaches to clinical trial designs have been developed that can be used to study new treatments for patients with rare cancers, thereby addressing a significant unmet need.<\/jats:p>","DOI":"10.1093\/neuonc\/noab209","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:46:04Z","timestamp":1631101564000},"page":"S30-S38","source":"Crossref","is-referenced-by-count":8,"title":["Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-0492","authenticated-orcid":false,"given":"Terri S","family":"Armstrong","sequence":"first","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"5","key":"2021110207361857500_CIT0001","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell."},{"issue":"6","key":"2021110207361857500_CIT0002","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","article-title":"MYCN amplification drives an aggressive form of spinal ependymoma","volume":"138","author":"Ghasemi","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021110207361857500_CIT0003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-020-00973-y","article-title":"High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma","volume":"8","author":"Raffeld","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"4","key":"2021110207361857500_CIT0004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/j.seminoncol.2016.07.002","article-title":"Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development","volume":"43","author":"Parchment","year":"2016","journal-title":"Semin Oncol."},{"issue":"4","key":"2021110207361857500_CIT0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/neuonc\/4.4.268","article-title":"Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies","volume":"4","author":"Lang","year":"2002","journal-title":"Neuro Oncol."},{"issue":"7489","key":"2021110207361857500_CIT0006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature13109","article-title":"C11orf95-RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma","volume":"506","author":"Parker","year":"2014","journal-title":"Nature."},{"issue":"6","key":"2021110207361857500_CIT0007","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol."},{"issue":"7848","key":"2021110207361857500_CIT0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","article-title":"Chromothripsis drives the evolution of gene amplification in cancer","volume":"591","author":"Shoshani","year":"2021","journal-title":"Nature."},{"issue":"3","key":"2021110207361857500_CIT0009","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/neuonc\/nou162","article-title":"Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients","volume":"17","author":"Vera-Bolanos","year":"2015","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021110207361857500_CIT0010","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-18-2572","article-title":"Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism","volume":"25","author":"Prabhu","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021110207361857500_CIT0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro Oncol."},{"issue":"19","key":"2021110207361857500_CIT0012","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med."},{"issue":"3","key":"2021110207361857500_CIT0013","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/neuonc\/noaa240","article-title":"A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma","volume":"23","author":"Gilbert","year":"2021","journal-title":"Neuro Oncol."},{"issue":"17","key":"2021110207361857500_CIT0014","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-13-0753","article-title":"New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs","volume":"20","author":"J\u00fcrgensmeier","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021110207361857500_CIT0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2021110207361857500_CIT0016","first-page":"4","article-title":"Clinical outcome assessments in neuro-oncology: a regulatory perspective","volume":"3","author":"Sul","year":"2016","journal-title":"Neurooncol Pract."},{"issue":"3","key":"2021110207361857500_CIT0017","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(18)30004-4","article-title":"Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative","volume":"19","author":"Dirven","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2021110207361857500_CIT0018","first-page":"18","article-title":"Evaluation of financial toxicity (FT) in people with rare central nervous system (CNS) tumors using an innovative web-based study design","volume":"48","author":"Timmer","year":"2021","journal-title":"Oncology Nursing Forum"},{"issue":"3","key":"2021110207361857500_CIT0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cncr.30355","article-title":"Clinical presentation and outcomes for adult ependymoma patients","volume":"123","author":"Acquaye","year":"2017","journal-title":"Cancer."},{"issue":"2","key":"2021110207361857500_CIT0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nur.20116","article-title":"Predictors of distress in caregivers of persons with a primary malignant brain tumor","volume":"29","author":"Sherwood","year":"2006","journal-title":"Res Nurs Health."},{"issue":"2","key":"2021110207361857500_CIT0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1188\/11.ONF.149-155","article-title":"Changes in caregiver perceptions over time in response to providing care for a loved one with a primary malignant brain tumor","volume":"38","author":"Hricik","year":"2011","journal-title":"Oncol Nurs Forum."},{"key":"2021110207361857500_CIT0022","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/neuonc\/nov166","article-title":"The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"2021110207361857500_CIT0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-006-9135-z","article-title":"Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)","volume":"80","author":"Armstrong","year":"2006","journal-title":"J Neurooncol."},{"issue":"4","key":"2021110207361857500_CIT0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3171\/2009.10.SPINE0943","article-title":"Reliability and validity of the M.D. Anderson Symptom Inventory-Spine Tumor Module","volume":"12","author":"Armstrong","year":"2010","journal-title":"J Neurosurg Spine."},{"key":"2021110207361857500_CIT0025","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1093\/neuonc\/nov270","article-title":"Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)","volume":"18","author":"Helfer","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"2021110207361857500_CIT0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA."},{"key":"2021110207361857500_CIT0027","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1093\/neuonc\/nov270","article-title":"Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)","volume":"18","author":"Helfer","year":"2016","journal-title":"Neuro Oncol."},{"key":"2021110207361857500_CIT0028","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","article-title":"Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report","volume":"21","author":"Armstrong","year":"2020","journal-title":"Lancet Oncol."},{"key":"2021110207361857500_CIT0029","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1188\/21.ONF.E3","article-title":"National Institute of Nursing Research, National Cancer Institute, and Oncology Nursing Society Research Colloquium Abstracts","volume":"48","author":"Vera","year":"2021","journal-title":"Oncol Nurs Forum."},{"key":"2021110207361857500_CIT0030","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/nov267","article-title":"Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: panel 1 report","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/Supplement_5\/S30\/41043051\/noab209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/Supplement_5\/S30\/41043051\/noab209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T07:36:54Z","timestamp":1635838614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/Supplement_5\/S30\/6415394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":30,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2021,11,2]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab209","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}